Viewing Study NCT05858203


Ignite Creation Date: 2025-12-24 @ 7:42 PM
Ignite Modification Date: 2025-12-26 @ 4:59 AM
Study NCT ID: NCT05858203
Status: RECRUITING
Last Update Posted: 2023-05-15
First Post: 2023-03-24
Is NOT Gene Therapy: True
Has Adverse Events: False

Brief Title: Inhibition of Che-1/AATF as a New Tool in Multiple Myeloma Treatment
Sponsor: Regina Elena Cancer Institute
Organization:

Study Overview

Official Title: Inhibition of Che-1/AATF as a New Tool in Multiple Myeloma Treatment
Status: RECRUITING
Status Verified Date: 2023-03
Last Known Status: None
Delayed Posting: No
If Stopped, Why?: Not Stopped
Has Expanded Access: False
If Expanded Access, NCT#: N/A
Has Expanded Access, NCT# Status: N/A
Acronym: AATF/Che-1
Brief Summary: Multiple myeloma (MM) is a haematological malignancy characterized by the accumulation of proliferating antibody producing plasma cells in the bone marrow. In the last few years many studies have emphasized the biological complexity and heterogeneity of MM as a result of both genetic and epigenetic aberrations. Che-1/AATF (Che-1) is a transcriptional cofactor involved in cell cycle regulation, apoptosis, DNA damage and stress response. it can be hypothesized that Che-1 might contribute to the establishment of the MM malignant phenotype by sustaining global transcription through its ability to modulate chromatin accessibility.

The prospective study on MM human samples aims to understand the involvement of Che-1 in the transcriptional regulation and chromatin remodeling during the pathology. To this goal the main objectives are:

* Characterization of Che-1's role in chromatin remodeling and global gene expression
* Study in vivo and in vitro of Che-1 involvement in MM tumorigenesis
* Evaluation of Che-1 as a possible therapeutic target
Detailed Description: None

Study Oversight

Has Oversight DMC: False
Is a FDA Regulated Drug?: False
Is a FDA Regulated Device?: False
Is an Unapproved Device?: None
Is a PPSD?: None
Is a US Export?: None
Is an FDA AA801 Violation?: